rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Sandy Macrae

President, CEO and Director

Company insider

Files Form 4 as: President, CEO and Director, Sangamo Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
54
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
1
Companies where not an officer
0
First trade
3 Jun 2016
Last trade
25 May 2026
Last filed
27 May 2026

Companies traded

Where they are an officer
Sangamo TherapeuticsDirector, Officer · Biotechnology · last 25 May 20260 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
25 May 2026filed 27 May 2026Sangamo TherapeuticsBiotechnologySEC FORM 4 Code F$2,19812,613 at $0.1743filing
25 May 2026filed 27 May 2026Sangamo TherapeuticsSEC FORM 4 Code F$2,14412,613 at $0.17filing
1 Apr 2026filed 3 Apr 2026Sangamo Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—2,500,000 at $0.00filing
1 Apr 2026filed 3 Apr 2026Sangamo Therapeuticsoption or derivativeSEC FORM 4 Code A—2,500,000 at $0.00filing
25 Feb 2026filed 26 Feb 2026Sangamo TherapeuticsBiotechnologySEC FORM 4 Code F$16K33,637 at $0.47filing
25 Feb 2026filed 26 Feb 2026Sangamo TherapeuticsSEC FORM 4 Code F$16K33,637 at $0.47filing
24 Feb 2026filed 26 Feb 2026Sangamo TherapeuticsBiotechnologySEC FORM 4 Code F$2,5005,291 at $0.4725filing
24 Feb 2026filed 26 Feb 2026Sangamo TherapeuticsSEC FORM 4 Code F$2,4875,291 at $0.47filing
22 Jan 2026filed 26 Jan 2026Sangamo TherapeuticsBiotechnologySEC FORM 4 Code F$41K102,950 at $0.3985filing
22 Jan 2026filed 26 Jan 2026Sangamo TherapeuticsSEC FORM 4 Code F$41K102,950 at $0.40filing
24 Nov 2025filed 26 Nov 2025Sangamo TherapeuticsSEC FORM 4 Code F$3,1457,488 at $0.42filing
22 Oct 2025filed 24 Oct 2025Sangamo TherapeuticsSEC FORM 4 Code F$84K126,950 at $0.66filing
24 Aug 2025filed 26 Aug 2025Sangamo TherapeuticsSEC FORM 4 Code F$4,4187,488 at $0.59filing
22 Jul 2025filed 24 Jul 2025Sangamo TherapeuticsSEC FORM 4 Code F$61K126,950 at $0.48filing
24 May 2025filed 28 May 2025Sangamo TherapeuticsSEC FORM 4 Code F$3,5197,488 at $0.47filing
22 Apr 2025filed 24 Apr 2025Sangamo TherapeuticsSEC FORM 4 Code F$99K126,950 at $0.78filing
25 Feb 2025filed 26 Feb 2025Sangamo Therapeuticsoption or derivativeSEC FORM 4 Code A—1,750,000 at $0.00filing
25 Feb 2025filed 26 Feb 2025Sangamo TherapeuticsSEC FORM 4 Code F$10K10,663 at $0.96filing
25 Feb 2025filed 26 Feb 2025Sangamo TherapeuticsSEC FORM 4 Code A—375,000 at $0.00filing
24 Feb 2025filed 26 Feb 2025Sangamo TherapeuticsSEC FORM 4 Code F$7,4887,488 at $1.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Scott B. WilloughbySVP, Chief Legal Officer, Secy · SVP, Chief Legal Officer, Secy at Sangamo Therapeutics, filing Form 4 there in the last year
Nathalie Dubois-StringfellowSVP-Chief Development Officer · SVP-Chief Development Officer at Sangamo Therapeutics, filing Form 4 there in the last year
Gregory D. DavisHead of Research & Technology · Head of Research & Technology at Sangamo Therapeutics, filing Form 4 there in the last year
Nikunj JainPrincipal Accounting Officer · Principal Accounting Officer at Sangamo Therapeutics, filing Form 4 there in the last year
Prathyusha DuraibabuDirector · Principal Financial Officer at Sangamo Therapeutics, filing Form 4 there in the last year